Back to search

Article

High HER2 intratumoral heterogeneity is a predictive factor for poor prognosis in Early-stage and Locally Advanced HER2-positive Breast Cancer

2024-02-20

Abstract excerpt

PURPOSE: Breast cancer tumors frequently have intratumor heterogeneity. Tumors with high intratumor heterogeneity have caused therapeutic resistance and have human epidermal growth factor receptor 2 (HER2) heterogeneity in response to HER2-targeted therapies. This study aimed to investigate whether high HER2 heterogeneity levels were clinically related to poor prognosis for HER2-targeted adjuvant therapies resista...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
43848e81-b7fc-5515-b2b9-db0e7864db0b
DOI
10.20944/preprints202402.1136.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
High HER2 intratumoral heterogeneity is a predictive factor for poor prognosis in Early-stage and Locally Advanced HER2-positive Breast CancerDOI 10.20944/preprints202402.1136.v1
Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumorsSemantic proximity
Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumorsSemantic proximity
Tumor Heterogeneity in Breast CancerSemantic proximity
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Semantic proximity
Tumoral heterogeneity of breast cancerSemantic proximity
Cancer-related gene mutations and intratumoral genetic heterogeneity in human epidermal growth factor receptor 2 heterogeneous gastric cancer.Semantic proximity
Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and GuidelinesSemantic proximity
Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.Semantic proximity
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.Semantic proximity
Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatmentSemantic proximity
Breast Cancer Heterogeneity and Response to Novel TherapeuticsSemantic proximity
<i>HER2</i> genetic heterogeneity in breast carcinomaSemantic proximity
Select a neighboring publication to make it the new centre.